Spots Global Cancer Trial Database for A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
Official Title: A Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients With CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission With Incomplete Platelet Recovery at High Risk for Early Relapse
Study ID: NCT01632852
Conditions
Interventions
Study Description
Brief Summary: This is a first in human, prospective, multicenter, nonrandomized, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and immunogenicity of repeat doses of CSL362.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Robert H. Lurie Comprehensive Cancer Center of Northwestern University Medical School, Chicago, Illinois, United States
Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Weill Cornell Medical College, New York, New York, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States
Royal Melbourne Hospital, Parkville, Victoria, Australia
Contact Details
Name: Dr. Mark DeWitte
Affiliation: CSL Limited
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
